Vitamin D for Isolated Systolic Hypertension (VitDISH)

Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN92186858

Enrollment

180

Registered

2008-08-21

Start date

2009-02-01

Completion date

Unknown

Last updated

2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Isolated systolic hypertension Circulatory System Essential (primary) hypertension

Interventions

100,000 units of vitamin D3 or placebo every 3 months for 1 year.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged greater than or equal to 70 years, either sex 2. Office systolic blood pressure (BP) greater than 140 mmHg 3. Serum 25 hydroxy vitamin D less than 75 nmol/L

Exclusion criteria

Exclusion criteria: 1. Hypertension known to be due to a correctable underlying medical or surgical cause 2. Diastolic blood pressure greater than 90 mmHg 3. Systolic blood pressure greater than 180 mmHg 4. Estimated glomerular filtration rate less than 40 ml/min (by four-variable modification of diet in renal disease rate [MDRD] equation) 5. Liver function tests (alanine aminotransferase [ALT], bilirubin, alkaline phosphatase) greater than 3 x normal 6. Corrected calcium greater than 2.60 mmol/L or less than 2.15 mmol/L 7. Known metastatic malignancy or sarcoidosis 8. Clinical diagnosis of osteomalacia 9. History of renal calculi 10. Diagnosis of heart failure with left ventricular systolic dysfunction 11. Atrial fibrillation 12. Already taking vitamin D supplements (consumption of fish oils will not be a contraindication to enrolment) 13. Unable to give written informed consent

Design outcomes

Primary

Measure	Time frame
Change in office blood pressure at 3 months	—

Secondary

Measure	Time frame
1. Change in office blood pressure at 0, 6, 9, 12 months 2. Change in 24 hour mean blood pressure at 0, 3, 6, 9, 12 months 3. Change in B-type natriuretic peptide, high sensitivity C-reactive protein (hsCRP) and homeostatic model assessment (HOMA) index at 0, 3 and 12 months 4. Change in endothelial function measured by flow-mediated dilatation of the brachial artery (FMD) at 0, 3 and 12 months 5. Change in pulse wave velocity at 0, 3 and 12 months 6. Change in 25-hydroxy vitamin D and parathyroid hormome (PTH) levels, cholesterol and triglycerides	—

Measure

Time frame

1. Change in office blood pressure at 0, 6, 9, 12 months 2. Change in 24 hour mean blood pressure at 0, 3, 6, 9, 12 months 3. Change in B-type natriuretic peptide, high sensitivity C-reactive protein (hsCRP) and homeostatic model assessment (HOMA) index at 0, 3 and 12 months 4. Change in endothelial function measured by flow-mediated dilatation of the brachial artery (FMD) at 0, 3 and 12 months 5. Change in pulse wave velocity at 0, 3 and 12 months 6. Change in 25-hydroxy vitamin D and parathyroid hormome (PTH) levels, cholesterol and triglycerides

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 10, 2026